Phase II trial of combination therapy with metronomic capecitabine (C) and fulvestrant (F) in the treatment of hormone receptor-positive metastatic breast cancer (HR plus MBC)

被引：0
|
作者：
Blakely, L. J.
Schwartzberg, L. S.
Wang, G.
Somer, B. G.
Wheeler, B. M.
Stepanski, E. J.
Walker, M.
Johns, A.
机构：
[1] West Clin, Memphis, TN USA
[2] Adv Med Specialties, Miami, FL USA
[3] ACORN Res, Memphis, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e11087
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11087
引用
收藏
页数：1
相关论文
共 50 条
  • [21] registHER: Treatment outcomes in patients with HER2-positive (HER2+), hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Tripathy, D.
    Kaufman, P.
    Brufsky, A.
    Mayer, M.
    Yood, M.
    Wang, L.
    Brammer, M.
    Yardley, D.
    Tan-Chiu, E.
    Rugo, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [22] Targeted combination therapy with fulvestrant (FUL) for second-line (2L) treatment of hormone receptor-positive (HR plus ) advanced breast cancer (ABC).
    Mayer, Ingrid A.
    O'Regan, Ruth
    Kornblum, Noah Saul
    Blackwell, Kimberly L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [23] Phase I/II study of letrozole and sorafenib as first-line therapy of hormone-receptor positive (HR plus ) metastatic breast cancer (MBC).
    Tan, Antoinette R.
    Wong, Serena Tsan-Lai
    Warren, Robert D.
    Eng-Wong, Jennifer
    Liu, Minetta C.
    Zelnak, Amelia Bruce
    Lin, Yong
    Shih, Weichung
    Ganesan, Shridar
    Grana, Generosa
    Isaacs, Claudine
    Toppmeyer, Deborah
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] Phase II Trial of Anastrozole Plus Goserelin in the Treatment of Hormone Receptor-Positive, Metastatic Carcinoma of the Breast in Premenopausal Women
    Carlson, Robert W.
    Theriault, Richard
    Schurman, Christine M.
    Rivera, Edgardo
    Chung, Cathie T.
    Phan, See-Chun
    Arun, Banu
    Dice, Kristine
    Chiv, Vivian Y.
    Green, Marjorie
    Valero, Vicente
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (25) : 3917 - 3921
  • [25] Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: The Phase III MECCA Trial
    Hong, Ruo-Xi
    Xu, Fei
    Xia, Wen
    Teng, Yue-E
    Ouyang, Qu-Chang
    Zheng, Qiu-Fan
    Yuan, Zhong-Yu
    Chen, Dong-Shao
    Jiang, Kui-Kui
    Lin, Ying
    Dai, Zhen
    Liu, Xin-Lan
    Chen, Qian-Jun
    Wu, Xin-Hong
    Shi, Yan-Xia
    Huang, Jia-Jia
    An, Xin
    Xue, Cong
    Bi, Xi-Wen
    Chen, Mei-Ting
    Li, Hui
    Yao, He-Rui
    Zou, Guo-Rong
    Huang, Heng
    Zhang, Jing-Min
    Wang, Shu-Sen
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (11)
  • [26] Clinical efficacy and molecular effects of lenvatinib (Len) and letrozole (Let) in hormone receptor-positive (HR plus ) metastatic breast cancer (MBC).
    Lim, Joline Si Jing
    Wong, Andrea
    Ow, Samuel Guan Wei
    Ngoi, Natalie
    Ang, Yvonne Li'en
    Chan, Gloria
    Eng, Lim Siew
    Chong, Wan Qin
    Choo, Joan
    Lee, Matilda
    Tan, Hon Lyn
    Jan, Yi-hua
    Tan, Kien Thiam
    Sundar, Raghav
    Tan, David Shao Peng
    Soo, Ross A.
    Chee, Cheng Ean
    Yong, Wei-Peng
    Goh, Boon C.
    Lee, Soo-Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Tumor genomics and response to CDK 4/6 inhibitors for patients with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC).
    Spring, Laura
    Niemierko, Andrzej
    Juric, Dejan
    Zangardi, Mark
    Abraham, Elizabeth
    Dias-Santagata, Dora
    Ellisen, Leif W.
    Isakoff, Steven J.
    Iafrate, A. John
    Moy, Beverly
    Bardia, Aditya
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [28] Phase I/II trial of palbociclib in combination with bicalutamide for the treatment of androgen receptor (AR) plus metastatic breast cancer (MBC)
    Gucalp, Ayca
    Edelweiss, Marcia
    Patil, Sujata
    Gounder, Mrinal M.
    Feigin, Kimberly N.
    Corben, Adriana
    Arumov, Artavazd
    Traina, Tiffany A.
    CANCER RESEARCH, 2018, 78 (04)
  • [29] Phase I/II trial of palbociclib in combination with bicalutamide for the treatment of androgen receptor (AR) plus metastatic breast cancer (MBC).
    Gucalp, Ayca
    Proverbs-Singh, Tracy Ann
    Corben, Adriana
    Moynahan, Mary Ellen
    Patil, Sujata
    Boyle, Leigh Ann
    Hudis, Clifford A.
    Traina, Tiffany A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] Durable response to fulvestrant therapy in a hormone receptor-positive metastatic breast cancer patient with massive metastatic disease
    Czartoryska-Arlukowicz, Bogumila
    ONCOLOGY IN CLINICAL PRACTICE, 2014, 10 (06): : 344 - 346
12345